Investing.com - Tandem Diabetes Care (NASDAQ: TNDM) reported third quarter EPS of $-0.35, $0.06 better than the analyst estimate of $-0.41. Revenue for the quarter came in at $244M versus the consensus estimate of $223.66M.
Guidance
Tandem Diabetes Care sees FY 2024 revenue of $903.00M-$910.00M versus the analyst consensus of $891.00M.
Tandem Diabetes Care's stock price closed at $34.24. It is down -8.69% in the last 3 months and up 110.58% in the last 12 months.
Tandem Diabetes Care saw 0 positive EPS revisions and 12 negative EPS revisions in the last 90 days. See Tandem Diabetes Care's stock price’s past reactions to earnings here.
According to InvestingPro, Tandem Diabetes Care's Financial Health score is "fair performance".
Check out Tandem Diabetes Care's recent earnings performance, and Tandem Diabetes Care's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar